<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-554
Date of Submission: 2024-12-22

This report was submitted by a Patient from Anderson Group Medical Center concerning patient ANON-PX-7957. The subject is an adult other with a significant medical history including chronic kidney disease, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin administered via the Intravenous route at a dosage of 166mg, initiated on 2024-10-20 for Neuropathic pain with the course ongoing; Omeprazole (Proton-pump inhibitor) administered via the Intramuscular route at a dosage of 151mg, initiated on 2024-10-20 for Gastroesophageal reflux disease with the course ongoing.

On approximately 2024-12-02, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Somnolence, Dizziness. The Somnolence was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed least and advised born. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2024-554
report_date: '2024-12-22'
patient_details:
  patient_id: ANON-PX-7957
  gender: Other
  relevant_history:
  - chronic kidney disease
  - migraines
suspected_drugs:
- drug_name: Gabapentin
  dosage: 166mg
  route_of_administration: Intravenous
  start_date: '2024-10-20'
  indication_for_use: Neuropathic pain
- drug_name: Omeprazole
  dosage: 151mg
  route_of_administration: Intramuscular
  start_date: '2024-10-20'
  indication_for_use: Gastroesophageal reflux disease
  drug_class: Proton-pump inhibitor
adverse_reactions:
- symptom_name: Somnolence
  onset_date: '2024-12-02'
  severity: Life-threatening
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Dizziness
  onset_date: '2024-12-02'
  severity: Life-threatening
  outcome: Unknown
  intervention_required: true
  intervention_details: Prescribed least and advised born.
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive dechallenge
reporting_facility: Anderson Group Medical Center
reporter_type: Patient
